The impact of nanotechnology in the treatment of Parkinson’s disease (PD) has been briefed in this review. A therapy can be analyzed and optimized only by understanding the pathology of the disease. Among all the drugs of PD therapy, levodopa remains the gold standard. The introduction of levodopa in the late 1960s represented a landmark in the therapy of PD and the remarkable efficacy of levodopa on the akinesia, tremor and rigidity of Parkinson's disease remains incontestable. Nanointervention is necessitated by the fact that only 1% of levodopa crosses the blood-brain-barrier. Nanotechnological application to the PD therapy is a recent advancement and opens up a huge possibility of research and development in this area.
Loading....